Skip to main content
News & Announcements , Articles & Publications , Nazim Kanji

Nazim Kanji contributes to taste masking insights article with PharmTech

Hexagons on blue gradient background with Quotient Sciences logo

Taste masking for oral dosage forms is a crucial aspect of formulation development. 

Nazim Kanji, Executive Director of Pediatric Services at Quotient Sciences, comments on taste masking strategies in a recent article with PharmTech.

Thoughtful design and development of drug products are vital for ensuring patient acceptability and compliance, which ultimately contribute to achieving the desired clinical outcomes. In a recent article with PharmTech, Nazim Kanji, Executive Director of Pediatric Services at Quotient Sciences, comments on taste masking strategies that drug developers and their CRDMO partners should keep in mind. 

Numerous active pharmaceutical ingredients (APIs) have a bitter taste, texture, or undesirable qualities that make it a challenge to create palatable medications. “Undesirable taste is a common issue in medicines across all therapeutic areas, from antibiotics and painkillers to antihistamines and decongestants,” he notes. He discusses reverse-enteric polymers, one strategy being used for taste masking due to their pH-dependent solubility, among other factors that should be considered. 

Read the full article, Evolving Approaches to Taste Masking, at the PharmTech website.

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, commercial manufacturing, Dr. Helen Baker, Dr. Richard Castledine Dr. Helen Baker and Dr. Richard Castledine contribute to Pharmaceutical Technology's 'Poor API Quality Threatens a Healthy Supply' By: Dr. Helen Baker and Dr. Richard Castledine
Read More
News & Announcements, Articles & Publications, Thierry Van Nieuwenhove Thierry Van Nieuwenhove on the Future of CDMO Partnerships By: Thierry Van Nieuwenhove
Read More
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Read More
Get in touch
Humanity can't afford to wait, so neither can we.